Académique Documents
Professionnel Documents
Culture Documents
h.weingart@jacobs-university.de
Plan for today
1. What is HTS?
2. Examples
3. General HTS equipment
4. Lecture plan
5. Milestones
6. Textbooks
HTS
Target
Target
assay design
assay validation
HTS
engineer
HTS implementation
Decision
Decisionmaking
making
Dr. Maxim Zakhartsev
Drug discovery today
disease
target
hit compounds
Drug
develop
lead compounds
ment
candidate drug
drug
drug on market
disease
1. Biology & Molecular 1. Phase I
science
2. Bioscience 2. Phase II
Drug
3. Combinatorial chemistry develop 3. Phase III
ment
4. Medical chemistry 4. New Drug Application
drug on market
Market examination
- Are the competing
agents already exists ?
- Would be it possible to drug on market
produce a betters drug
at lower price ?
- Patents review
2. Bioscience
disease
2.1 Screening
- Assay design
- Assay validation Drug
- Compound library develop
- HTS implementation ment
- Data handling
- Result interpretation
drug on market
2. Bioscience
disease
2.2 Confirming biological
activity
- Biochemical-based HTS
- hit compounds Drug
- repeatability develop
- concentration- ment
dependent effect
- Cell-based HTS
- hit the target without
damaging the cell
2. Bioscience
disease
2.3 Determining characteristics
- Pharmacokinetic assays on cell
cultures Drug
- Absorption develop
- Distribution ment
- Metabolism
- Secretion
drug on market
2. Bioscience
disease
2.4 Countering resistance
Assays on cell cultures to
determine how long a
compound remains active
Drug
before being broken down develop
- it should reach its
ment
target before being
degraded
- the level of the active
compound in vivo should
remain sufficiently high
for long enough time to
avoid resistance drug on market
development
HC-R1
Combinatorial
CombinatorialHC-R2
HC-R chemistry and drug on market
chemistry andHC-R3
HTS are closely
HTS are closely
linked!
linked! HC-R4
HC-R
Dr. Maxim Zakhartsev
Drug discovery today
4. Medical chemistry
disease
Lead optimization
- arrays of lead compounds
- a lead compound
forms the initial basis Drug
for an extensive
develop
synthesis program
ment
- lead evaluation and
selection by HTS p
Candidate Drug
drug on market
disease 1. Phase I
- initial test on human
- pharmacokinetic
properties & safety
Drug profile
develop
- blood concentration
ment
- healthy volunteers
(20-50)
Phase
PhaseIItrials
trialsare
areproving
proving
that
thataaparticular
particularcompound
compound
drug on market isissafe
safefor
foruse
useininhumans
humans
disease 2. Phase II
- test on patients
- medicinal effect
Drug - dosage
develop - side-effect
ment - patients suffering
form the disease
(100-500)
Phase
PhaseII IIhas
hasto
toshow
showthat
that
the compound has the
the compound has the
drug on market intended
intendedmedicinal
medicinaleffect
effect
and
and to determinethe
to determine the
optimal
optimaldosage
dosage
Phase
PhaseIIIIIIhas
hasto
toshow
show
that
that the new drug ismore
the new drug is more
efficient
efficientthan
thanthe
thebest
best
drug on market
existing
existingtreatments.
treatments.
Most
Most expensivepart
expensive part
- submitted to relevant
registration authorities for
Drug examination and approval
develop
ment
This
Thisphase
phasemay
mayneed
need
up to one year
up to one year
drug on market
HTS
HTS
Lead
Target Hit Lead CD Drug
optimization
HTS
Lead
Target Hit Lead CD Drug
optimization
HTS
Lead
Target Hit Lead CD Drug
optimization
Target
Target
assay design
assay validation
HTS
engineer
HTS implementation
Decision
Decisionmaking
making
try An
is ch alyt
em em ica
o ch ist l
Bi ry
Mo
l
bio ecul r ing
log ar in ee
y g
En
HTS I HTS II
Fall semester Spring semester
Examinations
Examinations
16-Oct Midterm
?-Dec Final exam